この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2012/4/251 分で読めます
AstraZeneca Pharmaceuticals LP; Withdrawal of Approval of a New Drug Application for IRESSA
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA) is withdrawing approval of a new drug application (NDA) for IRESSA (gefitinib) Tablets held by AstraZeneca Pharmaceuticals LP (AstraZeneca), 1800 Concord Pike, P.O. Box 8355, Wilmington, DE 19803-8355. AstraZeneca has voluntarily requested that approval of this application be withdrawn, thereby waiving its opportunity for a hearing.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →